A Phase 2 interventional study of pegfilgrastim and filgrastim in Sarcoma and Neutropenia, sponsored by Amgen. Completed. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2010-02-26.
Sponsored by Amgen · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Physicians are conducting a clinical trial for patients with pediatric sarcoma. Sarcoma is a type of bone cancer that can be treated with chemotherapy which can affect the bone marrow, where blood cells are produced. Neutrophils are a type of white blood cells that fight infection and are produced in the bone marrow. If the neutrophil count becomes too low due to chemotherapy, a potentially serious condition called neutropenia occurs. Neutropenia is serious because it can affect the body's ability to protect against many types of infections. Pegfilgrastim is an investigational drug being evaluated for its potential ability to increase the number of neutrophils. The purpose of this study is to determine the safety and effectiveness of pegfilgrastim in preventing neutropenia following chemotherapy in pediatric patients up through the age of 21 with sarcoma.
1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
This study's enrollment of 44 is close to the median of 41 across 1,254 interventional studies indexed under Sarcoma.
Browse Sarcoma studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Filgrastim
Drug: filgrastim
Pegfilgrastim
Drug: pegfilgrastim
pegfilgrastim
filgrastim
Duration of severe neutropenia in chemotherapy in cycles 1 and 3
Time frame: cycles 1 and 3
Time to ANC recovery to greater than or equal to 0.5 x 10^9/L in cycles 1 and 3
Time frame: cycles 1 and 3
Pharmacokinetic profile in chemotherapy cycles 1 and 3
Time frame: cycles 1 and 3
Incidence of adverse events across all cycles of chemotherapy
Time frame: all cycles
Overall rates of febrile neutropenia
Time frame: all cycles
No study locations are listed for this record.
The record gives a start of Apr 2000, a primary completion of Jan 2007 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegfilgrastim